Marker Total Current Assets vs Property Plant And Equipment Gross Analysis
MRKR Stock | USD 4.10 0.07 1.68% |
Marker Therapeutics financial indicator trend analysis is infinitely more than just investigating Marker Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Marker Therapeutics is a good investment. Please check the relationship between Marker Therapeutics Total Current Assets and its Property Plant And Equipment Gross accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.
Total Current Assets vs Property Plant And Equipment Gross
Total Current Assets vs Property Plant And Equipment Gross Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Marker Therapeutics Total Current Assets account and Property Plant And Equipment Gross. At this time, the significance of the direction appears to have very week relationship.
The correlation between Marker Therapeutics' Total Current Assets and Property Plant And Equipment Gross is 0.29. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Property Plant And Equipment Gross in the same time period over historical financial statements of Marker Therapeutics, assuming nothing else is changed. The correlation between historical values of Marker Therapeutics' Total Current Assets and Property Plant And Equipment Gross is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Marker Therapeutics are associated (or correlated) with its Property Plant And Equipment Gross. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Gross has no effect on the direction of Total Current Assets i.e., Marker Therapeutics' Total Current Assets and Property Plant And Equipment Gross go up and down completely randomly.
Correlation Coefficient | 0.29 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Property Plant And Equipment Gross
Most indicators from Marker Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Marker Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.As of 05/18/2024, Enterprise Value is likely to grow to about 27.1 M, while Selling General Administrative is likely to drop slightly above 5.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 3.2M | 3.7M | 4.2M | 2.3M | Interest Income | 5.7K | 248.1K | 447.2K | 291.5K |
Marker Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Marker Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Marker Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 46.4M | 45.6M | 68.1M | 34.4M | 17.1M | 13.6M | |
Other Current Liab | 30.7K | 10.0 | 6.0M | 3.1M | 2.1M | 2.4M | |
Total Current Liabilities | 2.0M | 6.4M | 12.9M | 7.8M | 3.1M | 4.6M | |
Total Stockholder Equity | 44.1M | 27.3M | 44.0M | 19.6M | 14.1M | 7.1M | |
Property Plant And Equipment Net | 873.2K | 21.2M | 22.2M | 17.8M | 20.5M | 21.5M | |
Net Debt | (43.4M) | (9.1M) | (30.5M) | (4.2M) | (15.1M) | (14.4M) | |
Retained Earnings | (327.5M) | (356.2M) | (398.1M) | (428.0M) | (436.3M) | (414.5M) | |
Accounts Payable | 993K | 2.9M | 5.1M | 1.6M | 961.2K | 1.3M | |
Cash | 43.9M | 21.4M | 42.4M | 11.8M | 15.1M | 9.6M | |
Cash And Short Term Investments | 43.9M | 21.4M | 42.4M | 11.8M | 15.1M | 9.6M | |
Net Receivables | 56.2K | 1.0M | 237.0 | 2.4M | 1.0M | 1.1M | |
Common Stock Total Equity | 10.6K | 45.4K | 45.7K | 50.7K | 58.3K | 41.4K | |
Common Stock Shares Outstanding | 4.6M | 4.7M | 7.7M | 8.4M | 8.8M | 9.2M | |
Liabilities And Stockholders Equity | 46.4M | 45.6M | 68.1M | 34.4M | 17.1M | 13.6M | |
Non Current Liabilities Total | 1.6M | 280.2K | 11.9M | 11.2M | 7.0M | 0.0 | |
Other Current Assets | 1.5M | 3.1M | 3.6M | 2.4M | 988.1K | 581.5K | |
Other Stockholder Equity | 371.6M | 383.5M | 442.0M | 447.6M | 450.3M | 472.8M | |
Total Liab | 2.3M | 18.3M | 24.1M | 14.8M | 3.1M | 6.0M | |
Property Plant And Equipment Gross | 873.2K | 21.2M | 24.9M | 17.8M | 20.5M | 21.5M | |
Total Current Assets | 45.5M | 24.4M | 46.0M | 16.6M | 17.1M | 10.3M | |
Short Term Debt | 204.1K | 388.8K | 620.5K | 577.2K | 519.5K | 481.1K | |
Common Stock | 45.7K | 50.7K | 83.1K | 8.4K | 8.9K | 8.4K | |
Non Currrent Assets Other | (472.0) | (21.2M) | 2.2M | (17.8M) | (16.0M) | (15.2M) | |
Net Tangible Assets | 59.3M | 44.1M | 27.3M | 44.0M | 50.6M | 53.1M | |
Capital Surpluse | 161.1M | 365.4M | 371.6M | 383.5M | 441.1M | 230.6M | |
Net Invested Capital | 44.1M | 27.3M | 44.0M | 19.6M | 14.1M | 24.2M | |
Net Working Capital | 43.5M | 18.0M | 33.1M | 8.8M | 14.1M | 20.6M | |
Capital Stock | 45.7K | 50.7K | 83.1K | 8.4K | 8.9K | 8.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Marker Stock analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Marker Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.375 | Quarterly Revenue Growth 0.008 | Return On Assets (0.38) | Return On Equity (0.88) |
The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.